Aldeyra The (ALDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aldeyra The (ALDX) has a cash flow conversion efficiency ratio of -0.143x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.02 Million) by net assets ($49.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Aldeyra The to measure how many days the company can operate on defensive assets alone.
Aldeyra The - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Aldeyra The's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aldeyra The Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aldeyra The ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vacasa Inc
NASDAQ:VCSA
|
-0.736x |
|
Loxley Public Company Limited
BK:LOXLEY
|
-0.044x |
|
Critical Holdings Berhad
KLSE:0291
|
-0.070x |
|
Concorde International Group Ltd.
NASDAQ:YOOV
|
N/A |
|
Buda Juice, Inc.
NYSE MKT:BUDA
|
0.129x |
|
Monroe Capital Corp
NASDAQ:MRCC
|
-0.011x |
|
Concorde International Group Ltd Class A Ordinary Shares
NASDAQ:CIGL
|
N/A |
|
Comet Ridge Ltd
AU:COI
|
-0.023x |
Annual Cash Flow Conversion Efficiency for Aldeyra The (2011–2024)
The table below shows the annual cash flow conversion efficiency of Aldeyra The from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see ALDX company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $71.00 Million | $-43.21 Million | -0.609x | -140.38% |
| 2023-12-31 | $119.80 Million | $-30.33 Million | -0.253x | +32.50% |
| 2022-12-31 | $151.01 Million | $-56.64 Million | -0.375x | -81.32% |
| 2021-12-31 | $205.74 Million | $-42.56 Million | -0.207x | +67.17% |
| 2020-12-31 | $59.51 Million | $-37.49 Million | -0.630x | +32.66% |
| 2019-12-31 | $48.08 Million | $-44.98 Million | -0.936x | -171.42% |
| 2018-12-31 | $86.62 Million | $-29.86 Million | -0.345x | +28.99% |
| 2017-12-31 | $39.60 Million | $-19.22 Million | -0.485x | +30.62% |
| 2016-12-31 | $21.65 Million | $-15.15 Million | -0.700x | -86.93% |
| 2015-12-31 | $24.88 Million | $-9.31 Million | -0.374x | +50.75% |
| 2014-12-31 | $6.28 Million | $-4.78 Million | -0.760x | +28.08% |
| 2013-12-31 | $1.61 Million | $-1.71 Million | -1.057x | -3516.77% |
| 2012-12-31 | $-25.15 Million | $-778.05K | 0.031x | -96.98% |
| 2011-12-31 | $-2.33 Million | $-2.39 Million | 1.025x | -- |
About Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatm… Read more